World's Best Scientists 2026 revealed!
Thomas Valerius

Thomas Valerius

D-Index & Metrics

Immunology

D-Index
50
Citations
9366
World Ranking
4244
National Ranking
282

Thomas Valerius publication distribution in Immunology in 2026

The chart shows the distribution of publications by all Research.com ranked scientists in the field of Immunology in 2026. The highlighted bar marks where Thomas Valerius sits on this spectrum.

62–71 publications: 9 scientists 72–81 publications: 23 scientists 82–91 publications: 40 scientists 92–101 publications: 72 scientists 102–111 publications: 86 scientists 112–121 publications: 108 scientists 122–131 publications: 150 scientists 132–141 publications: 160 scientists 142–151 publications: 159 scientists 152–161 publications: 189 scientists 162–171 publications: 166 scientists 172–181 publications: 181 scientists 182–191 publications: 188 scientists 192–201 publications: 187 scientists 202–211 publications: 178 scientists 212–221 publications: 158 scientists 222–231 publications: 168 scientists 232–241 publications: 159 scientists 242–251 publications: 160 scientists 252–261 publications: 148 scientists 262–271 publications: 116 scientists 272–281 publications: 125 scientists 282–291 publications: 115 scientists 292–301 publications: 111 scientists 302–311 publications: 95 scientists 312–321 publications: 97 scientists 322–331 publications: 97 scientists 332–341 publications: 99 scientists 342–351 publications: 96 scientists 352–361 publications: 68 scientists 362–371 publications: 76 scientists 372–381 publications: 71 scientists 382–391 publications: 71 scientists 392–401 publications: 62 scientists 402–411 publications: 54 scientists 412–421 publications: 41 scientists 422–431 publications: 63 scientists 432–441 publications: 53 scientists 442–451 publications: 31 scientists 452–461 publications: 42 scientists 462–471 publications: 40 scientists 472–481 publications: 29 scientists 482–491 publications: 34 scientists 492–501 publications: 30 scientists 502–511 publications: 23 scientists 512–521 publications: 41 scientists 522–531 publications: 29 scientists 532–541 publications: 28 scientists 542–551 publications: 16 scientists 552–561 publications: 18 scientists 562–571 publications: 18 scientists 572–581 publications: 17 scientists 582–591 publications: 17 scientists 592–601 publications: 17 scientists 602–611 publications: 19 scientists 612–621 publications: 13 scientists 622–631 publications: 12 scientists 632–641 publications: 11 scientists 642–651 publications: 16 scientists 652–661 publications: 9 scientists 662–671 publications: 5 scientists 672–681 publications: 13 scientists 682–691 publications: 12 scientists 692–701 publications: 6 scientists 702–711 publications: 6 scientists 712–721 publications: 9 scientists 722–731 publications: 9 scientists 732–741 publications: 6 scientists 742–751 publications: 11 scientists 752–761 publications: 10 scientists 762–771 publications: 7 scientists 772–781 publications: 12 scientists 782–791 publications: 7 scientists 792–801 publications: 5 scientists 802–806 publications: 1 scientists 807+ publications: 100 scientists
62 publications 807+

This scientist: 194 publications — 32nd percentile

32% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 807 publications or more.

Thomas Valerius D-index placement in Immunology in 2026

The chart shows the D-index (discipline H-index) distribution of Immunology scientists ranked by Research.com in 2026. The highlighted bar marks where Thomas Valerius sits on this spectrum.

40–41 D-Index: 28 scientists 42–43 D-Index: 91 scientists 44–45 D-Index: 157 scientists 46–47 D-Index: 192 scientists 48–49 D-Index: 175 scientists 50–51 D-Index: 188 scientists 52–53 D-Index: 177 scientists 54–55 D-Index: 155 scientists 56–57 D-Index: 194 scientists 58–59 D-Index: 201 scientists 60–61 D-Index: 197 scientists 62–63 D-Index: 201 scientists 64–65 D-Index: 173 scientists 66–67 D-Index: 167 scientists 68–69 D-Index: 172 scientists 70–71 D-Index: 199 scientists 72–73 D-Index: 184 scientists 74–75 D-Index: 133 scientists 76–77 D-Index: 162 scientists 78–79 D-Index: 127 scientists 80–81 D-Index: 121 scientists 82–83 D-Index: 125 scientists 84–85 D-Index: 121 scientists 86–87 D-Index: 102 scientists 88–89 D-Index: 96 scientists 90–91 D-Index: 75 scientists 92–93 D-Index: 72 scientists 94–95 D-Index: 74 scientists 96–97 D-Index: 66 scientists 98–99 D-Index: 68 scientists 100–101 D-Index: 49 scientists 102–103 D-Index: 60 scientists 104–105 D-Index: 54 scientists 106–107 D-Index: 36 scientists 108–109 D-Index: 23 scientists 110–111 D-Index: 52 scientists 112–113 D-Index: 41 scientists 114–115 D-Index: 34 scientists 116–117 D-Index: 25 scientists 118–119 D-Index: 28 scientists 120–121 D-Index: 11 scientists 122–123 D-Index: 20 scientists 124–125 D-Index: 27 scientists 126–127 D-Index: 19 scientists 128–129 D-Index: 20 scientists 130–131 D-Index: 16 scientists 132–133 D-Index: 17 scientists 134–135 D-Index: 14 scientists 136–137 D-Index: 15 scientists 138–139 D-Index: 9 scientists 140–141 D-Index: 11 scientists 142–143 D-Index: 9 scientists 144–145 D-Index: 9 scientists 146–147 D-Index: 7 scientists 148–149 D-Index: 7 scientists 150–151 D-Index: 7 scientists 152–153 D-Index: 5 scientists 154–155 D-Index: 8 scientists 156 D-Index: 6 scientists 157+ D-Index: 96 scientists
40 D-Index 157+

This scientist: 50 D-Index — 15th percentile

15% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 157 D-Index or more.

Overview

Thomas Valerius is affiliated with Kiel University in Germany. Their research primarily spans the fields of Medicine and Immunology and Microbiology, with a focus on several interconnected subfields including Immunology, Hematology, Radiology, Nuclear Medicine and Imaging, Oncology, and Public Health, Environmental and Occupational Health.

Their work extensively covers key topics such as Monoclonal and Polyclonal Antibodies Research, Immune Cell Function and Interaction, Hematopoietic Stem Cell Transplantation, Acute Lymphoblastic Leukemia research, CAR-T cell therapy research, Glycosylation and Glycoproteins Research, and Phagocytosis and Immune Regulation.

Valerius has published papers in several frequent venues, including Blood, Frontiers in Immunology, Bone Marrow Transplantation, bioRxiv (Cold Spring Harbor Laboratory), and the Journal for ImmunoTherapy of Cancer.

Selected recent papers include:

  • "Discovery of amivantamab (JNJ-61186372), a bispecific antibody targeting EGFR and MET" (2021, Journal of Biological Chemistry)
  • "Augmented antibody-based anticancer therapeutics boost neutrophil cytotoxicity" (2021, Journal of Clinical Investigation)
  • "Human IgG Fc-engineering for enhanced plasma half-life, mucosal distribution and killing of cancer cells and bacteria" (2024, Nature Communications)
  • "Combining daratumumab with CD47 blockade prolongs survival in preclinical models of pediatric T-ALL" (2022, Blood)
  • "Dual checkpoint blockade of CD47 and LILRB1 enhances CD20 antibody-dependent phagocytosis of lymphoma cells by macrophages" (2022, Frontiers in Immunology)

Frequent co-authors include Matthias Peipp, Jeanette H.W. Leusen, Thies Rösner, Christian Kellner, and Denis M. Schewe.

Best Publications

  • Daratumumab, a novel therapeutic human CD38 monoclonal antibody, induces killing of multiple myeloma and other hematological tumors

    Michel De Weers;Yu Tzu Tai;Michael S. Van Der Veer;Joost M. Bakker

  • Characterization of new human CD20 monoclonal antibodies with potent cytolytic activity against non-Hodgkin lymphomas

    Jessica L Teeling;Ruth R French;Mark S Cragg;Jeroen van den Brakel

  • Neutrophils express the high affinity receptor for IgG (Fc gamma RI, CD64) after in vivo application of recombinant human granulocyte colony-stimulating factor.

    R. Repp;Th. Valerius;A. Sendler;M. Gramatzki

  • Human IgG2 Antibodies against Epidermal Growth Factor Receptor Effectively Trigger Antibody-Dependent Cellular Cytotoxicity but, in Contrast to IgG1, Only by Cells of Myeloid Lineage

    Tanja Schneider-Merck;Jeroen J. Lammerts van Bueren;Sven Berger;Kai Rossen

  • Antibody fucosylation differentially impacts cytotoxicity mediated by NK and PMN effector cells.

    Matthias Peipp;Jeroen J. Lammerts van Bueren;Tanja Schneider-Merck;Wim W. K. Bleeker

  • Complement-dependent tumor cell lysis triggered by combinations of epidermal growth factor receptor antibodies.

    Michael Dechant;Wencke Weisner;Sven Berger;Matthias Peipp

  • Involvement of the high-affinity receptor for IgG (Fc gamma RI; CD64) in enhanced tumor cell cytotoxicity of neutrophils during granulocyte colony-stimulating factor therapy

    T. Valerius;R. Repp;T. P. M. De Wit;S. Berthold

  • FcαRI (CD89) as a Novel Trigger Molecule for Bispecific Antibody Therapy

    Thomas Valerius;Bernhard Stockmeyer;Annemiek B. van Spriel;Robert F. Graziano

  • Triggering Fc alpha-receptor I (CD89) recruits neutrophils as effector cells for CD20-directed antibody therapy.

    Bernhard Stockmeyer;Michael Dechant;Marjolein van Egmond;Alison L. Tutt

  • HLA class II as potential target antigen on malignant B cells for therapy with bispecific antibodies in combination with granulocyte colony-stimulating factor

    D. Elsässer;T. Valerius;R. Repp;G. J. Weiner

  • Discovery of amivantamab (JNJ-61186372), a bispecific antibody targeting EGFR and MET.

    Joost Neijssen;Rosa M.F. Cardoso;Kristen M. Chevalier;Luus Wiegman

  • Potent Fc Receptor Signaling by IgA Leads to Superior Killing of Cancer Cells by Neutrophils Compared to IgG.

    Arianne M. Brandsma;Sina Bondza;Mitchell Evers;Rosanne Koutstaal

  • Preclinical Studies with FcγR Bispecific Antibodies and Granulocyte Colony-stimulating Factor-primed Neutrophils as Effector Cells against HER-2/neu Overexpressing Breast Cancer

    Bernhard Stockmeyer;Thomas Valerius;Roland Repp;Ingmar A. F. M. Heijnen

  • IgA EGFR antibodies mediate tumour killing in vivo

    Peter Boross;Stefan Lohse;Maaike Nederend;Johannes Hendrik Marco Jansen

  • Phase I clinical trial of the bispecific antibody MDX-H210 (anti-FcgammaRI x anti-HER-2/neu) in combination with Filgrastim (G-CSF) for treatment of advanced breast cancer.

    R Repp;H H van Ojik;T Valerius;G Groenewegen

  • Bispecific antibodies targeting cancer cells.

    Matthias Peipp;Thomas Valerius

  • Chimeric IgA antibodies against HLA class II effectively trigger lymphoma cell killing.

    Michael Dechant;Gestur Vidarsson;Bernhard Stockmeyer;Roland Repp

  • Effector Mechanisms of Recombinant IgA Antibodies against Epidermal Growth Factor Receptor

    Michael Dechant;Thomas Beyer;Tanja Schneider-Merck;Wencke Weisner

  • FcγRIIIb Restricts Antibody-Dependent Destruction of Cancer Cells by Human Neutrophils

    Louise W. Treffers;Michel van Houdt;Christine W. Bruggeman;Marieke H. Heineke

  • Evaluating antibodies for their capacity to induce cell-mediated lysis of malignant B cells.

    Würflein D;Dechant M;Stockmeyer B;Tutt Al

  • Polymorphonuclear granulocytes induce antibody-dependent apoptosis in human breast cancer cells

    Bernhard Stockmeyer;Thomas Beyer;Winfried Neuhuber;Roland Repp

  • Effective lysis of lymphoma cells with a stabilised bispecific single-chain Fv antibody against CD19 and FcgammaRIII (CD16).

    Joerg Bruenke;Karin Barbin;Susanne Kunert;Peter Lang

  • Combined Fc-protein- and Fc-glyco-engineering of scFv-Fc fusion proteins synergistically enhances CD16a binding but does not further enhance NK-cell mediated ADCC

    Roland Repp;Christian Kellner;Anja Muskulus;Matthias Staudinger

  • Involvement of the high-affinity receptor for IgG (Fc gamma RI; CD64) in enhanced tumor cell cytotoxicity of neutrophils during granulocyte colony-stimulating factor therapy.

    Unknown

Frequent Co-Authors

Matthias Peipp
Matthias Peipp Kiel University
Jan G. J. van de Winkel
Jan G. J. van de Winkel Genmab (United States)
Paul W. H. I. Parren
Paul W. H. I. Parren Leiden University Medical Center
Jeanette H. W. Leusen
Jeanette H. W. Leusen Utrecht University
Martin Schrappe
Martin Schrappe Kiel University
Timo K. van den Berg
Timo K. van den Berg Radboud University
Martin J. Glennie
Martin J. Glennie University of Southampton
Joachim R. Kalden
Joachim R. Kalden University of Erlangen-Nuremberg
Gestur Vidarsson
Gestur Vidarsson University of Amsterdam
Georg H. Fey
Georg H. Fey University of Erlangen-Nuremberg

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

For those interested in Immunology, pursuing related healthcare and nursing degrees online can open diverse career pathways. Many programs cater specifically to individuals without a nursing background, such as online RN programs for non nurses. These programs provide a streamlined route to becoming a registered nurse, combining foundational healthcare knowledge with specialized skills.

If you are looking for faster entry into the nursing field, some of the easiest accelerated nursing programs are designed to help students quickly earn their Bachelor of Science in Nursing (BSN). These programs often offer flexibility for working professionals or those changing careers.

For a more focused nursing role, easiest LPN programs to get into provide accessible pathways to becoming a Licensed Practical Nurse (LPN), which can serve as a foundation for advancing in nursing or immunology-related fields.

Lastly, to advance clinical expertise and leadership, easiest nurse practitioner program options allow nurses to specialize further and take on more responsibilities in patient care, including immunology-related practices.

Best Scientists Citing Thomas Valerius

Trending Scientists

Recently Published Articles